G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance. You knew this would happen, yes? To cope, we are relying, as always, on cups of stimulation. Our choice today is laced with traces of cocoa. Feel free to join us. Remember, no prescription is required. Meanwhile, here are some tidbits to help you along. Best of luck accomplishing your goals today and, of course, do keep in touch …

Sanofi (SNY) agreed to pay $11.6 billion for Bioverativ, a spinoff from Biogen (BIIB) that will catapult the big drug maker into the market for treatments for rare blood disorders. The deal is the biggest by Sanofi in several years after failed efforts to buy Medivation and Actelion, and comes as  the French drug maker struggles to offset declines for its best-selling Lantus insulin and its struggling diabetes franchise.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.